Presence of Species in Gastric Mucosa of Human Patients and Outcome of Eradication Treatment.

The genus is composed of bacteria that colonize both the human and animal gastrointestinal tract. infects half of the world's population, causing various disorders, such as gastritis, duodenitis and gastric cancer. Additionally, non- species (NHPH) are commonly found in the stomach of pigs, dogs and cats. Most of these species have zoonotic potential and prevalence rates of 0.2-6.0%, and have been described in human patients suffering from gastric disorders undergoing a gastric biopsy. The aim of this study was to determine the occurrence of spp. in the stomach of patients with gastric cancer ( = 17) and obese ( = 63) patients. Furthermore, the outcome of the eradication treatment and the current infection status was evaluated. Overall, based on the genus-specific PCR followed by sequencing, DNA from spp. was detected in 46.3% of the patients, including single infections with in 43.8% of the patients and mixed infections with and canine- or feline-associated in 2.5%. About 32.5% of the patients had been subjected to previous eradication therapy and the triple standard therapy was the most frequent scheme (42.3%). In 48.0% of the patients who received eradication treatment, bacteria were still detected, including one mixed infection. In 23.1% of the patients who reported that a subsequent test had been performed to confirm the elimination of the bacteria, were still detected. In conclusion, although in a smaller percentage, NHPH may also be present in the human stomach. Thus, specific NHPH screening should be included in the diagnostic routine. The continued presence of in the stomach of patients recently subjected to eradication schemes raises questions about the efficacy of the current treatments.